{"publication_id":"8b15f6df-c45d-4575-89cb-441c5de831bd","content_hash":"sha256:d170178dd79ad64f15a13656001f91f83d808905b635976093b90414311945fe","nodes":[{"id":"8b15f6df-c45d-4575-89cb-441c5de831bd","type":"publication","title":"Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy"},{"id":"claim_1","type":"claim","text":"Headline:** Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy"},{"id":"claim_2","type":"claim","text":"The cited A/B receipts support a specific working claim: reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837); users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis."},{"id":"claim_3","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_4","type":"claim","text":"The discordance between acarbose's pronounced male-specific lifespan extension in genetically heterogeneous mice and its female-preferential dementia risk reduction in human type 2 diabetes patients suggests that sex-hormone interactions or differential gut-brain axis modulation may underpin its geroprotective effects, inviting mechanistic studies beyond glucose lowering."},{"id":"claim_5","type":"claim","text":"Real tension: Acarbose increased median lifespan by 22% in male mice but only 5% in female mice (facts 3,4), whereas in human T2D patients, it reduced dementia risk only in women with an HR of 0.783 (fact 12)."},{"id":"claim_6","type":"claim","text":"`fact_id=187300` (`A_core`) — reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837) doi=10.14336/ad.2019.0621"},{"id":"claim_7","type":"claim","text":"`fact_id=187299` (`A_core`) — users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925) doi=10.14336/ad.2019.0621"},{"id":"claim_8","type":"claim","text":"`fact_id=135514` (`A_core`) — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups. doi=10.3346/jkms.2014.29.1.90"},{"id":"claim_9","type":"claim","text":"`fact_id=70369` (`A_core`) — Acarbose increased male median lifespan by 22% (P < 0.0001) doi=10.1111/acel.12170"},{"id":"claim_10","type":"claim","text":"`fact_id=135510` (`A_core`) — acarbose produced 51% decrease in maltose loaded diabetic rats doi=10.4236/jdm.2012.21013"},{"id":"claim_11","type":"claim","text":"`fact_id=108410` (`A_core`) — significantly increased (3%) in females only at 1,000 ppm doi=10.1111/acel.12898"},{"id":"claim_12","type":"claim","text":"_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._"},{"id":"claim_13","type":"claim","text":"Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0."},{"id":"claim_14","type":"claim","text":"Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version."},{"id":"source_1","type":"source","study":"Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone","year":2020,"doi":"10.14336/ad.2019.0621","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study","year":2014,"doi":"10.3346/jkms.2014.29.1.90","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.","year":2014,"doi":"10.1111/acel.12170","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats","year":2012,"doi":"10.4236/jdm.2012.21013","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Acarbose improves health and lifespan in aging HET3 mice","year":2019,"doi":"10.1111/acel.12898","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"**Topic:** `acarbose`","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_7","type":"source","study":"**Author:** Dom Lynch","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_8","type":"source","study":"**ORCID:** _not configured_","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_9","type":"source","study":"**Version:** 1.0","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_10","type":"source","study":"**License:** CC BY-NC 4.0","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_11","type":"source","study":"**Canonical URL:** _not assigned_","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_12","type":"source","study":"**Suggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_13","type":"source","study":"**Run bundle SHA-256:** `3d52b42b2eef9077a0c62041abf8adb8d43ceebe45f152cf94dee9baec1ad512`","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_14","type":"source","study":"**Memo SHA-256:** `91120f14f4fab94a9d4c0b507c6b9d9cbc242e9a9636797539d71156d94b7ffc`","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_15","type":"source","study":"**Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_1","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_2","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_3","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_4","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_5","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_6","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_7","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_8","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_9","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_10","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_11","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_12","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_13","type":"contains_claim"},{"from":"8b15f6df-c45d-4575-89cb-441c5de831bd","to":"claim_14","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}